Screening and Surveillance for Pancreatic Adenocarcinoma in High-Risk Individuals

Arielle J. Labiner; Anne Aronson; Aimee L. Lucas

doi:10.1016/j.hoc.2022.06.004

Screening and Surveillance for Pancreatic Adenocarcinoma in High-Risk Individuals

Arielle J. Labiner, Anne Aronson, Aimee L. Lucas

Research output: Contribution to journal › Review article › peer-review

Abstract

Pancreatic ductal adenocarcinoma (PDAC) is an aggressive disease with high mortality, largely due to late stage at diagnosis. Approximately 10% to 15% are hereditary, and detection of early stage PDAC or precursor lesions through pancreatic surveillance programs may improve outcomes. Current surveillance is annual, typically with endoscopic ultrasound and/or magnetic resonance imaging.

Original language	English
Pages (from-to)	929-942
Number of pages	14
Journal	Hematology/Oncology Clinics of North America
Volume	36
Issue number	5
DOIs	https://doi.org/10.1016/j.hoc.2022.06.004
State	Published - Oct 2022

Keywords

Cancer screening
Consensus guidelines
Familial pancreatic cancer
High-risk
Pancreatic ductal adenocarcinoma
Pancreatic surveillance

Access to Document

10.1016/j.hoc.2022.06.004

Cite this

@article{5966210390c1459486e12137940b6cac,

title = "Screening and Surveillance for Pancreatic Adenocarcinoma in High-Risk Individuals",

abstract = "Pancreatic ductal adenocarcinoma (PDAC) is an aggressive disease with high mortality, largely due to late stage at diagnosis. Approximately 10% to 15% are hereditary, and detection of early stage PDAC or precursor lesions through pancreatic surveillance programs may improve outcomes. Current surveillance is annual, typically with endoscopic ultrasound and/or magnetic resonance imaging.",

keywords = "Cancer screening, Consensus guidelines, Familial pancreatic cancer, High-risk, Pancreatic ductal adenocarcinoma, Pancreatic surveillance",

author = "Labiner, {Arielle J.} and Anne Aronson and Lucas, {Aimee L.}",

year = "2022",

month = oct,

doi = "10.1016/j.hoc.2022.06.004",

language = "English",

volume = "36",

pages = "929--942",

journal = "Hematology/Oncology Clinics of North America",

issn = "0889-8588",

publisher = "W.B. Saunders Ltd",

number = "5",

}

TY - JOUR

T1 - Screening and Surveillance for Pancreatic Adenocarcinoma in High-Risk Individuals

AU - Labiner, Arielle J.

AU - Aronson, Anne

AU - Lucas, Aimee L.

PY - 2022/10

Y1 - 2022/10

N2 - Pancreatic ductal adenocarcinoma (PDAC) is an aggressive disease with high mortality, largely due to late stage at diagnosis. Approximately 10% to 15% are hereditary, and detection of early stage PDAC or precursor lesions through pancreatic surveillance programs may improve outcomes. Current surveillance is annual, typically with endoscopic ultrasound and/or magnetic resonance imaging.

AB - Pancreatic ductal adenocarcinoma (PDAC) is an aggressive disease with high mortality, largely due to late stage at diagnosis. Approximately 10% to 15% are hereditary, and detection of early stage PDAC or precursor lesions through pancreatic surveillance programs may improve outcomes. Current surveillance is annual, typically with endoscopic ultrasound and/or magnetic resonance imaging.

KW - Cancer screening

KW - Consensus guidelines

KW - Familial pancreatic cancer

KW - High-risk

KW - Pancreatic ductal adenocarcinoma

KW - Pancreatic surveillance

UR - http://www.scopus.com/inward/record.url?scp=85140281408&partnerID=8YFLogxK

U2 - 10.1016/j.hoc.2022.06.004

DO - 10.1016/j.hoc.2022.06.004

M3 - Review article

C2 - 36265991

AN - SCOPUS:85140281408

SN - 0889-8588

VL - 36

SP - 929

EP - 942

JO - Hematology/Oncology Clinics of North America

JF - Hematology/Oncology Clinics of North America

IS - 5

ER -

Screening and Surveillance for Pancreatic Adenocarcinoma in High-Risk Individuals

Abstract

Keywords

Access to Document

Fingerprint

Cite this